Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis
Isaac E. Hall(University of Utah), Chirag R. Parikh(College of Medicine & JNM Hospital), Mark A. Perazella(Yale University), Umo U. Eko(VA Connecticut Healthcare System), Randy L. Luciano(Yale University), Steven G. Coca(Icahn School of Medicine at Mount Sinai), Patricia R. Peter(Beth Israel Deaconess Medical Center), Won Kon Han(Kangbuk Samsung Hospital)
Cited by 121
Related Papers
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
|Kidney International|2020|724
Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
|Radiology|2020|582
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
|JAMA Internal Medicine|2020|555